Accelerated radiotherapy with concomitant boost technique (69.5 Gy/5 weeks) : an alternative in the treatment of locally advanced head and neck cancer
Language English Country Germany Media print-electronic
Document type Journal Article
- MeSH
- Adult MeSH
- Radiotherapy, Conformal methods MeSH
- Middle Aged MeSH
- Humans MeSH
- Hypopharyngeal Neoplasms mortality pathology radiotherapy MeSH
- Nasopharyngeal Neoplasms mortality pathology radiotherapy MeSH
- Mouth Neoplasms mortality pathology radiotherapy MeSH
- Follow-Up Studies MeSH
- Otorhinolaryngologic Neoplasms mortality pathology radiotherapy MeSH
- Disease-Free Survival MeSH
- Radiation Injuries etiology MeSH
- Radiotherapy, Intensity-Modulated methods MeSH
- Aged MeSH
- Neoplasm Staging MeSH
- Feasibility Studies MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND AND PURPOSE: To present the feasibility and results of accelerated radiotherapy with concomitant boost technique (69.5 Gy/5 weeks) in the treatment of locally advanced head and neck cancer. PATIENTS AND METHODS: A total of 65 patients were treated between June 2006 and August 2009. The distribution of clinical stages was as follows: II 11%, III 23%, IV 61%, and not defined 5%. RESULTS: The median follow-up was 30.5 months. The treatment plan was completed in 94% of patients. Patients were treated using the conformal or intensity-modulated radiotherapy (IMRT) technique. The median overall treatment time was 37 days (13-45 days). The mean radiotherapy dose was 68.4 Gy (16-74 Gy). Overall survival was 69% after 2 years. Disease-free survival was 62% after 2 years. Acute toxicity ≥ grade 3(RTOG scale) included mucositis (grade 3: 42.6%), pharynx (grade 3: 42.3%), skin (grade 3: 9.5%), larynx (grade 3: 4%), while late toxicity affected skin (grade 3: 6.25%) and salivary glands (grade 3: 3.7%). CONCLUSION: Accelerated radiotherapy with concomitant boost technique is feasible in patients with locally advanced head and neck cancer, has an acceptable toxicity profile, and yields promising treatment results.
See more in PubMed
Strahlenther Onkol. 2010 Sep;186(9):511-6 PubMed
Clin Oncol (R Coll Radiol). 2008 Mar;20(2):113-26 PubMed
Radiother Oncol. 1994 Apr;31(1):14-22 PubMed
Lancet. 2003 Sep 20;362(9388):933-40 PubMed
Br J Radiol. 1994 Aug;67(800):790-4 PubMed
Strahlenther Onkol. 2009 Oct;185(10):682-8 PubMed
Radiother Oncol. 1997 Aug;44(2):123-36 PubMed
Radiother Oncol. 2009 Feb;90(2):166-71 PubMed
Clin Oncol (R Coll Radiol). 2008 Apr;20(3):212-20 PubMed
Strahlenther Onkol. 2010 Sep;186(9):489-95 PubMed
Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):62-9 PubMed
Radiother Oncol. 2005 Feb;74(2):93-100 PubMed
Clin Oncol (R Coll Radiol). 2007 Feb;19(1):8-22 PubMed
Curr Opin Oncol. 2004 May;16(3):215-9 PubMed
Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):807-19 PubMed
Radiother Oncol. 2003 Nov;69(2):161-8 PubMed
Strahlenther Onkol. 2009 Oct;185(10):675-81 PubMed
Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):7-16 PubMed
Radiother Oncol. 1996 Aug;40(2):137-45 PubMed
Radiother Oncol. 1992 Dec;25(4):231-41 PubMed
Lancet. 2000 Mar 18;355(9208):949-55 PubMed
N Engl J Med. 2006 Feb 9;354(6):567-78 PubMed
